BioCardia
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1999-01-01
- Employees
- 20
- Market Cap
- -
- Website
- http://www.biocardia.com
- Introduction
BioCardia, Inc. is a clinical-stage biotherapeutic company. It engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. The company was founded on January 12, 1994 and is headquartered in Sunnyvale, CA.
CardiAMP Heart Failure II Trial for Patients With Ischemic Heart Failure With Reduced Ejection Fraction
- Conditions
- Ischemic Heart Failure
- Interventions
- Device: Autologous bone marrow mononuclear cells processed / delivered using the CardiAMP cell therapy system
- First Posted Date
- 2024-02-14
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- BioCardia, Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT06258447
- Locations
- 🇺🇸
Morton Plant Hospital - BayCare, Clearwater, Florida, United States
Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cells
- Conditions
- Heart Failure, Systolic
- Interventions
- Combination Product: CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs)
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- BioCardia, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT05925608
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
AllogeneiC Expanded Human MSC Therapy in Patients Recovering From COVID-19 Acute Respiratory Distress Trial
- Conditions
- ARDS, Human
- Interventions
- Biological: intravenous delivery of allogeneic bone marrow-derived MSCs
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- BioCardia, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT05491681
CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial
- Conditions
- Chronic Myocardial IschemiaRefractory Angina
- Interventions
- Other: Sham TreatmentDevice: CardiAMP Cell Therapy System
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- BioCardia, Inc.
- Target Recruit Count
- 343
- Registration Number
- NCT03455725
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
🇺🇸University of Wisconsin Madison, Madison, Wisconsin, United States
CardiAMP™ Cell Therapy for Heart Failure Trial
- Conditions
- Heart Failure, Systolic
- Interventions
- Biological: Autologous cell therapyOther: Sham
- First Posted Date
- 2015-05-08
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- BioCardia, Inc.
- Target Recruit Count
- 125
- Registration Number
- NCT02438306
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸John Hopkins University School of Medicine - Dept of Cardiology, Baltimore, Maryland, United States
🇺🇸Atlantic Health System, Morristown, New Jersey, United States
Autologous Bone Marrow Transplanted Via Transendocardial Catheter to Chronic Myocardial Infarct Border Zone
- Conditions
- Ventricular DysfunctionMyocardial Infarction
- First Posted Date
- 2007-07-26
- Last Posted Date
- 2009-11-03
- Lead Sponsor
- BioCardia, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT00507468
- Locations
- 🇦🇷
Swiss Clinic, Buenos Aires, Argentina
🇦🇷Argentine Institute of Diagnosis and Treatment, Buenos Aires, Argentina